BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:38 PM
 | 
Oct 08, 2012
 |  BC Extra  |  Clinical News

Lilly tacks on $2.9B on additional solanezumab data

Eli Lilly and Co. (NYSE:LLY) added about $2.9 billion in market cap on Monday after reporting subgroup data from two Phase III trials of Alzheimer's disease product solanezumab that previously missed their primary endpoints. Pooled data from the...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >